The avian metapneumovirus treatment market value is expected to be approximately USD 311.6 million, which is anticipated to nearly double, reaching around USD 579.5 million by 2035. This market is ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Vermont has the second lowest state fatality rate in the US (148.5 per 100K; Hawaii 113.8/100K). Mississippi (466.2/100K) and Oklahoma (461.5/100K) have the highest rates. The US average is 308.2/100K ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

French pharma giant Sanofi announced on Tuesday that it is to purchase London-based respiratory virus vaccine developer ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond Lead asset VXB-241 is a bivalent vaccine ...

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...